Aqtual is a precision medicine company developing products for chronic disease management and oncology utilizing a novel cell-free DNA-based platform. Aqtual's proprietary platform evaluates protein regulation, epigenetics, and transcriptomics solely using cell-free DNA fragments found in the blood. The platform yields efficient and robust real-time analysis of disease and treatment while overcoming the limitations of previous cell-free DNA methodologies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/11/25 | $31,000,000 | Series B |
Bold Capital Genoa Ventures Manta Ray Ventures Yu Galaxy | undisclosed |
